![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Incidence and Determinants of Denial of DAA Therapy by Type of Insurance During the First 6 Months of the Modern HCV Treatment Era
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Vincent Lo Re, MD, MSCE
C Gowda, PN Urick, J Halladay, A Binkley, DM Carbonari, K Battista, C Peleckis, J Gilmore, JA Roy, KR Reddy,
JR Kostman
Division of Infectious Diseases
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania
![AASLD1.gif](../images/112315/112315-7/AASLD1.gif)
![AASLD2.gif](../images/112315/112315-7/AASLD2.gif)
![AASLD3.gif](../images/112315/112315-7/AASLD3.gif)
![AASLD4.gif](../images/112315/112315-7/AASLD4.gif)
![AASLD5.gif](../images/112315/112315-7/AASLD5.gif)
![AASLD6.gif](../images/112315/112315-7/AASLD6.gif)
![AASLD7.gif](../images/112315/112315-7/AASLD7.gif)
![AASLD8.gif](../images/112315/112315-7/AASLD8.gif)
![AASLD9.gif](../images/112315/112315-7/AASLD9.gif)
![AASLD10.gif](../images/112315/112315-7/AASLD10.gif)
![AASLD11.gif](../images/112315/112315-7/AASLD11.gif)
![AASLD12.gif](../images/112315/112315-7/AASLD12.gif)
![AASLD13.gif](../images/112315/112315-7/AASLD13.gif)
![AASLD14.gif](../images/112315/112315-7/AASLD14.gif)
![AASLD15.gif](../images/112315/112315-7/AASLD15.gif)
![AASLD16.gif](../images/112315/112315-7/AASLD16.gif)
![AASLD17.gif](../images/112315/112315-7/AASLD17.gif)
![AASLD18.gif](../images/112315/112315-7/AASLD18.gif)
![AASLD19.gif](../images/112315/112315-7/AASLD19.gif)
![AASLD20.gif](../images/112315/112315-7/AASLD20.gif)
![AASLD21.gif](../images/112315/112315-7/AASLD21.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|